Mode
Text Size
Log in / Sign up

Sperm DNA fragmentation and mitochondrial potential predict IVF outcomes in asthenozoospermia

Sperm DNA fragmentation and mitochondrial potential predict IVF outcomes in asthenozoospermia
Photo by National Cancer Institute / Unsplash
Key Takeaway
Consider sperm DFI and MMP as potential predictors for IVF outcomes in asthenozoospermic patients.

This retrospective cohort study, conducted from January 2023 to June 2024, evaluated 320 asthenozoospermic men and 100 controls with normal semen parameters undergoing IVF-embryo transfer. The study assessed sperm DNA fragmentation index (DFI), reactive oxygen species (ROS), and mitochondrial membrane potential (MMP) as exposures.

Asthenozoospermic patients showed significantly higher DFI and ROS and lower MMP compared to controls. In multivariate analysis, DFI and MMP were independent predictors of clinical pregnancy rate. The low DFI/high MMP group achieved significantly higher fertilization, pregnancy, and live birth rates than the high DFI/low MMP group. The combination of DFI and MMP had an AUC of 0.771 for predicting clinical pregnancy, greater than DFI alone (AUC = 0.643) or MMP alone (AUC = 0.651).

Safety and tolerability were not reported. Key limitations include the retrospective design and lack of reporting on whether the study was randomized or controlled for confounders beyond multivariate adjustment. The practice relevance suggests DFI and MMP assessment may guide patient management in assisted reproductive technologies for asthenozoospermic patients, but findings are associative only.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
ObjectiveTo investigate the levels of sperm DNA fragmentation index (DFI), reactive oxygen species (ROS), and mitochondrial membrane potential (MMP) in asthenozoospermic patients and assess their predictive value for in vitro fertilization (IVF) pregnancy outcomes.MethodsThis retrospective cohort study included 320 men with asthenozoospermic patients and 100 with normal semen parameters, assessed between January 2023 and June 2024. Of these, 143 couples undergoing IVF-embryo transfer were analyzed for outcomes. Semen samples were evaluated for conventional parameters, DFI, ROS, and MMP. Patients were stratified by DFI and MMP thresholds, and a combined DFI/MMP group was analyzed. Fertilization rate, cleavage rate, high-quality embryo rate, blastocyst formation rate, clinical pregnancy rate, miscarriage rate, and live birth rates were recorded. Multivariate logistic regression and receiver operating characteristic (ROC) curve analyses were performed.ResultsAsthenozoospermic patients showed significantly higher DFI and ROS, and lower MMP compared to controls, with these parameters correlating to asthenozoospermia severity. DFI and MMP were identified as independent predictors of clinical pregnancy rate via multivariate logistic regression. The high DFI group had significantly lower fertilization, pregnancy, and live birth rates than the low DFI group, while the high MMP group demonstrated superior outcomes across all metrics compared to the low MMP group. The low DFI/high MMP group achieved the best results, exhibiting significantly higher fertilization, pregnancy, and live birth rates than the high DFI/low MMP group. ROC curve analysis indicated that the combination of DFI and MMP provided greater predictive power for clinical pregnancy (AUC = 0.771) than DFI (AUC = 0.643) or MMP (AUC = 0.651) alone.ConclusionSperm DFI and MMP are confirmed as independent and clinically significant predictors of clinical pregnancy in asthenozoospermic patients undergoing IVF treatment. The combined assessment of DFI and MMP offers superior predictive utility for IVF pregnancy outcomes compared to the assessment of either marker alone. These findings underscore the critical role of these sperm quality parameters in assessing reproductive potential and suggest significant clinical utility for guiding patient management and optimizing treatment strategies in assisted reproductive technologies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.